MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
February 10 2022 - 6:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat at the SVB
Leerink 2022 Global Healthcare Conference on Thursday, February 17,
2022 at 1:00 pm (ET).
Interested parties can access a link to the webcast from the New
& Events section of the Company’s website at
http://www.mannkindcorp.com. The webcast replay will remain
available for 14 days following the live presentation.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
Company Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024